Premium
Midazolam versus dexamethasone‐ondansetron in preventing post‐operative nausea‐vomiting in patients undergoing laparoscopic surgeries
Author(s) -
Prakash Kelika,
Meshram Tanvi,
Jain Priyanka
Publication year - 2021
Publication title -
acta anaesthesiologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.738
H-Index - 107
eISSN - 1399-6576
pISSN - 0001-5172
DOI - 10.1111/aas.13813
Subject(s) - medicine , ondansetron , midazolam , anesthesia , antiemetic , postoperative nausea and vomiting , nausea , vomiting , dexamethasone , placebo , surgery , sedation , alternative medicine , pathology
Background Midazolam reduces post‐operative nausea and vomiting (PONV) when compared to a placebo or when used as an adjuvant to other antiemetics. The present study was designed to compare midazolam with a combination of dexamethasone‐ondansetron in preventing PONV. Methods One hundred and twenty patients undergoing laparoscopic surgeries having 2 or more risk factors for PONV (simplified Apfel score) were randomised into 2 groups of 60 each. Patients in group D received 8‐mg dexamethasone and 4‐mg ondansetron for PONV prophylaxis while those in group M received 2‐mg midazolam towards the end of surgery. The proportion of patients (frequency) who had PONV, post‐operative nausea (PON) and post‐operative vomiting (POV) was noted over 24 hours over the following intervals: 0‐2 hours, 2‐24 hours and 0‐24 hours. Results The frequency of PONV at 24 hours in group D and group M was 30% and 33.3% respectively and was not significantly different ( P = .70). There was no difference in the time to achieve post‐anaesthesia discharge score of ≥9 between the two groups {5 minutes (5, 5) in group D; 5 minutes (1.25, 5) in group M, P = .48}. Ten patients in group D and 11 in group M required a rescue antiemetic over 24 hours ( P = .81). The frequency of PON, POV and PONV as well as the median PONV score was similar at all time periods. Conclusion Midazolam does not result in significantly different frequency of PONV than a combination of dexamethasone‐ondansetron.